References
American Hospital Formulary Service (AHFS) Drug Information, pp. 448–449, 1991
Bishop-Freudling GB, Vergin H. Determination of 2,4-diamino5-benzylpyrimidines in combination with sulfadiazine in biological fluids using high-performance liquid chromatography. Journal of Chromatography — Biomedical Applications 224: 301–309, 1981
Goadsby PJ, Donaghy AJ, Lloyd AR, Wakefield D. Acquired immunodeficiency syndrome and sulfadiazine-associated acute renal failure (corresp.). Annals of Internal Medicine 107: 783–784, 1987
Kucers A, Bennett N.McK, Kemp RJ. The use of antibiotics, 4th ed., pp. 1075–1117, J.B. Lippincott Co., Philadelphia, 1987
Sahai J, Heimberger T, Collins K, Kaplowitz L, Polk R. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. American Journal of Medicine 84: 791–792, 1988
Springolo V, Coppi G. HPLC determination of tetroxoprim and sulfadiazine in pharmaceutical dosage forms and in biological fluids. Journal of Pharmaceutical and Biomedical Analysis 7: 57–65, 1989
Tang B-K, Kadar D, Qian L, Iriah J, Yip J, et al. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clinical Pharmacology and Therapeutics 49: 648–657, 1991
Ventura MG, Wybran J, Farber CM. Sulfadiazine revisited. Journal of Infectious Diseases 160: 556–557, 1989
Vree TB, O’Reilly WJ, Hekster YA, Damsma JE, van der Kleijn E. Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man. Clinical Pharmacokinetics 5: 274–294, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, M.A., Gallicano, K., Dascal, A. et al. Sulfadiazine Urolithiasis during Antitoxoplasma Therapy. Drug Invest 5, 334–337 (1993). https://doi.org/10.1007/BF03259241
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259241